At least two life sciences and biopharma hedge funds were rocked last month when the shares of one of their largest holdings plummeted in price following bad news, in what was yet another mostly rough month for the sector’s funds.
Avoro Capital Advisors was down 15 percent in July alone and is now off by 21 percent for the year, according to a person who has seen the results.
